Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include very common findings: Global developmental delay; and common findings: Low muscle tone (hypotonia), Secondary microcephaly, Refractory status epilepticus, and Focal-onset seizure. 18 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Bilateral tonic-clonic seizure, Clonic seizure, Brain shrinkage (cerebral atrophy) |
ATP1A2 encodes ATPase Na+/K+ transporting subunit alpha 2 (1,020 aa). This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. Highest expression in Muscle Skeletal (591.9 TPM) and Brain Caudate basal ganglia (555.4 TPM).
Developmental and epileptic encephalopathy 98 is associated with mutations in the ATP1A2 gene on chromosome 1.
The ATP1A2 protein participates in ATP1A:ATP1B:FXYD exchanges 3Na+ for 2K+ pathway.
ATP1A2 is classified as a druggable target (Cell Surface, Druggable Genome, Enzyme, Ion Channel, and Transporter categories) with score 0.8.
Consensus clinical diagnostic criteria for familial hemiplegic migraine (FHM) have been published by the (full text).
FHM is a category of migraine with aura. Note: Migraine with aura is a recurring disorder of neurologic symptoms unequivocally localizable to the cerebral cortex or brain stem. The aura usually develops over a period of five to 20 minutes and lasts less than 60 minutes. Headache, nausea, and/or photophobia usually follow neurologic aura symptoms, either immediately or after a symptom-free interval of less than an hour. The headache usually lasts four to 72 hours but may be completely absent (acephalgic migraine).
No approved treatments are currently available for developmental and epileptic encephalopathy 98. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with familial hemiplegic migraine (FHM) or simplex hemiplegic migraine (i.e., individuals with an FHM-causing pathogenic variant and an apparently negative family history), the evaluations summarized in this (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Familial Hemiplegic Migraine System/Concern | Evaluation Neurologic | • Quantitative eye movement exam in persons w/nystagmus or complaints of incoordination or imbalance to look for additional clues of cerebellar involvement • EEG neuroimaging studies if seizures are present in order to further characterize seizure disorder • Neuroimaging studies in those w/impaired responsiveness to assess for cerebral edema Assess for movement disorder in those w/PRRT2-FHM Genetic counseling | By genetics professionals1 to obtain a pedigree inform affected persons their families re nature, MOI, implications of FHM in order to facilitate medical personal decision making Family support resources | Assess need for: • Community or such as Parent to Parent; • Social work involvement for parental support; • Home nursing referral. FHM = familial hemiplegic migraine; MOI = mode of inheritance 1. Medical geneticist, certified genetic counselor, certified advanced genetic nurse Treatment of Manifestations Symptomatic support during an episode of hemiplegic migraine is the only therapy available. Table 5. Treatment of Manifestations in Individuals with Familial Hemiplegic Migraine
Table 6.
Recommended Surveillance for Individuals with Familial Hemiplegic Migraine
System/Concern | Evaluation | Frequency
| Eval by neurologist to assess change in attack frequency /or seizures, development of movement disorder, developmental delay, /or learning disability | Annually or more frequently for worsening symptoms
No clinical trials have been registered for developmental and epileptic encephalopathy 98.
39 publications have been identified in PubMed for developmental and epileptic encephalopathy 98. Research spans Epidemiology / Natural History (33%), Review / Meta-Analysis (15%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 13 | 33% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 1:05 PM UTC
Online Mendelian Inheritance in Man
Muscles |
3 |
Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia), Brain shrinkage (cerebral atrophy) |
Head and neck | 1 | Secondary microcephaly |
Lungs and breathing | 1 | Sleep apnea |
In migraine with aura, including familial hemiplegic migraine (FHM), the neurologic symptoms of aura are unequivocally localizable to the cerebral cortex or brain stem and include fully reversible visual disturbance (most common), sensory loss (e.g., numbness or paresthesias of the face or an extremity), and dysphasia (difficulty with speech), and for FHM must include motor involvement (e.g., hemiparesis [weakness of an extremity]):
Visual disturbances can include scotoma (blind spots), photopsia (flashing lights), fortification spectra (zigzag pattern), and diplopia (double vision).
Dysphasia usually occurs when hemiplegia is right-sided.
Hemiparesis (unilateral weakness), not necessarily hemiplegia (unilateral paralysis), occurs with at least one other symptom during FHM aura.
Source: GeneReviews — "Familial Hemiplegic Migraine"
ATP1A2
A severe phenotype with seizures, coma, and elevated temperature has been reported with the pathogenic variant in ATP1A2 .
A severe phenotype with seizures and intellectual disability has been reported with the pathogenic variants and .
CACNA1A. Although further correlation is needed, some suggestive genotype-phenotype correlations exist based on limited data regarding CACNA1A pathogenic variants commonly presenting with nystagmus and other cerebellar signs .
Source: GeneReviews — "Familial Hemiplegic Migraine"
Penetrance appears to be high and is estimated at 80% .
Source: GeneReviews — "Familial Hemiplegic Migraine"
Diagnostic criteria for HM
Source: GeneReviews — "Familial Hemiplegic Migraine"
Migraine without aura (OMIM 157300) (common migraine) is an idiopathic, recurring headache disorder manifesting in attacks lasting four to 72 hours. Typical characteristics of the headache are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity, and association with nausea, photophobia, and phonophobia. This headache occurs without neurologic aura symptoms and specifically without hemiparesis. Hemiplegia. The differential diagnosis of hemiplegia includes post-ictal weakness following seizure, transient ischemic attack, stroke, and other non-genetic causes of transient hemiparesis. Stroke.
Source: GeneReviews — "Familial Hemiplegic Migraine"
Genetic testing for ATP1A2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for developmental and epileptic encephalopathy 98 has been reported in the published literature.
Manifestation/Concern | Treatment | Considerations/Other |
|---|---|---|
Seizures | Anti-seizure treatment | — |
Cerebral edema | Corticosteroids in children w/cerebral edema to reduce life-threatening manifestations | ASM = anti-seizure medication Surveillance Table 6. |
Recommended Surveillance for Individuals with Familial Hemiplegic Migraine System/Concern | Evaluation | Frequency |
Neurologic | Eval by neurologist to assess change in attack frequency /or seizures, development of movement disorder, developmental delay, /or learning disability | Annually or more frequently for worsening symptoms Agents/Circumstances to Avoid In general, vasoconstricting agents should be avoided because of the risk of stroke. Cerebral angiography is hazardous as it may precipitate a severe attack . |
Source: GeneReviews — "Familial Hemiplegic Migraine"
In general, vasoconstricting agents should be avoided because of the risk of stroke. Cerebral angiography is hazardous as it may precipitate a severe attack .
Source: GeneReviews — "Familial Hemiplegic Migraine"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Familial Hemiplegic Migraine"
View trials for developmental and epileptic encephalopathy 98
Phenotype severity distribution: 1 very common feature, 4 common features.
Research summaries |
6 |
15% |
Clinical study results | 6 | 15% |
Laboratory research | 6 | 15% |
Testing and diagnosis research | 4 | 10% |
Patient case studies | 2 | 5% |
Other research | 1 | 3% |
New treatment approaches | 1 | 3% |
Acharya A (2026). [PMID: 41964217](https://pubmed.ncbi.nlm.nih.gov/41964217/). *HGG Adv*. [Basic Science / Preclinical]
Marini C (2026). [PMID: 41915870](https://pubmed.ncbi.nlm.nih.gov/41915870/). *Neurology*. [Epidemiology / Natural History]
Tailin L (2026). [PMID: 41260192](https://pubmed.ncbi.nlm.nih.gov/41260192/). *Epilepsy Res*. [Basic Science / Preclinical]
Wirrell E (2026). [PMID: 41321080](https://pubmed.ncbi.nlm.nih.gov/41321080/). *Epilepsia Open*. [Epidemiology / Natural History]
Chan R (2026). [PMID: 40884306](https://pubmed.ncbi.nlm.nih.gov/40884306/). *Clin Pharmacol Drug Dev*. [Clinical Trial Publication]
Routledge N (2025). [PMID: 40879121](https://pubmed.ncbi.nlm.nih.gov/40879121/). *Ann Neurol*. [Basic Science / Preclinical]
Maeda K (2025). [PMID: 40081203](https://pubmed.ncbi.nlm.nih.gov/40081203/). *Clin Neurophysiol*. [Epidemiology / Natural History]
Orgun LT (2025). [PMID: 39970743](https://pubmed.ncbi.nlm.nih.gov/39970743/). *Seizure*. [Case Report / Case Series]
Trivisano M (2025). [PMID: 39981956](https://pubmed.ncbi.nlm.nih.gov/39981956/). *Ann Neurol*. [Clinical Trial Publication]
Tobiasz A (2025). [PMID: 40934839](https://pubmed.ncbi.nlm.nih.gov/40934839/). *Seizure*. [Review / Meta-Analysis]